Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Rises By 11.4%

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 17,650,000 shares, a growth of 11.4% from the December 15th total of 15,840,000 shares. Based on an average daily trading volume, of 6,670,000 shares, the short-interest ratio is presently 2.6 days. Currently, 12.7% of the shares of the stock are sold short.

Bionano Genomics Stock Performance

Shares of NASDAQ:BNGO traded down $0.01 during trading hours on Friday, hitting $0.19. 7,196,647 shares of the company’s stock traded hands, compared to its average volume of 13,889,912. Bionano Genomics has a 52 week low of $0.18 and a 52 week high of $1.40. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. The company’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.38.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH lowered shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Hedge Funds Weigh In On Bionano Genomics

Several large investors have recently made changes to their positions in BNGO. Armistice Capital LLC bought a new position in shares of Bionano Genomics during the 2nd quarter valued at about $1,138,000. Carret Asset Management LLC lifted its stake in Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Bionano Genomics during the third quarter valued at about $46,000. Finally, Geode Capital Management LLC lifted its stake in Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares in the last quarter. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.